New drug could help teens shed pounds

NCT ID NCT07255209

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called IBI362 in 180 Chinese adolescents aged 12 to 17 who are obese or overweight and haven't lost enough weight with diet and exercise alone. Participants will receive either the drug or a placebo to see if it helps reduce body mass index (BMI) safely. The trial is double-blind, meaning neither the teens nor the doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI362 (a drug for weight loss)
What this could lead to: If successful, this could provide a new medication option for adolescents struggling with obesity or overweight.
What could go wrong: This is an early-stage trial with a small number of participants, and results may not apply to all teens. The drug may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES

Contacts and locations

Locations

The Children's Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.